All In Biotech

Drug Trial Radar · NCT00140049

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.

Last checked: Nov 20, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

238

Actual

Start

Jul 2005

Primary completion

Not stated

Study completion Jul 2006

Sponsor

Sponsor type
Industry
First posted
Aug 31, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon \& 4 PM during a 12 week treatment.

Conditions

  • Glaucoma, Open Angle
  • Ocular Hypertension

Interventions

  • XalacomDrug

  • CosoptDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean IOP measurements obtained in the study eye at each time point

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Caen, France

  • Pfizer Investigational Site

    Clermont-Ferrand, France

  • Pfizer Investigational Site

    Lyon, France

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Saint-Herblain, France

  • Pfizer Investigational Site

    Darmstadt, Germany

  • Pfizer Investigational Site

    Darmstadt, Germany

  • Pfizer Investigational Site

    Landau / Pfalz, Germany

  • Pfizer Investigational Site

    Regenstauf, Germany

  • Pfizer Investigational Site

    Schorndorf, Germany

  • Pfizer Investigational Site

    Starnberg, Germany

  • Pfizer Investigational Site

    Alexandroupoli, Greece

  • Pfizer Investigational Site

    Larissa, Greece

  • Pfizer Investigational Site

    Heraklion, Crete, Greece

  • Pfizer Investigational Site

    Thessaloniki, Macedonia, Greece

  • Pfizer Investigational Site

    Chieti, Italy

  • Pfizer Investigational Site

    Foggia, Italy

  • Pfizer Investigational Site

    Genova, Italy

  • Pfizer Investigational Site

    Milan, Italy

  • Pfizer Investigational Site

    Monza (MI), Italy

  • Pfizer Investigational Site

    Pisa, Italy

  • Pfizer Investigational Site

    örebro, Sweden

  • Pfizer Investigational Site

    Malmö, Sweden

  • Pfizer Investigational Site

    Mölndal, Sweden

  • Pfizer Investigational Site

    Sundsvall, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.